Tonix Pharmaceuticals Holding Corp. (TNXP) stock
TNXPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/3083% below fair value
$2.94+0.06 (+2.08%)
Close on Nov 17, 2026Market cap $50.42MP/E –Yield –
Tonix Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Tonix Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $63.86M, up 79.0% year over year. For fiscal 2025 it was $44.49M, up 11.3% from the year before. Over ten years it grew 2.3% a year on average. The highest annual figure on record is $86.66M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $44.49M | +11.3% |
| FY2024 | Dec 31, 2024 | $39.97M | -53.9% |
| FY2023 | Dec 31, 2023 | $86.66M | +5.8% |
| FY2022 | Dec 31, 2022 | $81.88M | +18.9% |
| FY2021 | Dec 31, 2021 | $68.84M | +90.4% |
| FY2020 | Dec 31, 2020 | $36.16M | +98.8% |
| FY2019 | Dec 31, 2019 | $18.19M | +3.6% |
| FY2018 | Dec 31, 2018 | $17.56M | +31.6% |
| FY2017 | Dec 31, 2017 | $13.34M | -53.2% |
| FY2016 | Dec 31, 2016 | $28.53M | -19.6% |
| FY2015 | Dec 31, 2015 | $35.50M | +90.7% |
| FY2014 | Dec 31, 2014 | $18.62M | +300.4% |
| FY2013 | Dec 31, 2013 | $4.65M | +80.0% |
| FY2012 | Dec 31, 2012 | $2.58M | +123.1% |
| FY2011 | Dec 31, 2011 | $1.16M | +98.2% |
| FY2010 | Dec 31, 2010 | $584.30K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $19.42M | +79.5% |
| Q1 FY2026 | Mar 31, 2026 | $18.21M | +144.9% |
| Q4 FY2025 | Dec 31, 2025 | $16.94M | +104.2% |
| Q3 FY2025 | Sep 30, 2025 | $9.29M | +1.9% |
| Q2 FY2025 | Jun 30, 2025 | $10.82M | +11.6% |
| Q1 FY2025 | Mar 31, 2025 | $7.44M | -42.2% |
| Q4 FY2024 | Dec 31, 2024 | $8.30M | -51.5% |
| Q3 FY2024 | Sep 30, 2024 | $9.11M | -56.7% |
| Q2 FY2024 | Jun 30, 2024 | $9.70M | -55.9% |
| Q1 FY2024 | Mar 31, 2024 | $12.86M | -51.5% |
| Q4 FY2023 | Dec 31, 2023 | $17.12M | -30.6% |
| Q3 FY2023 | Sep 30, 2023 | $21.05M | -5.2% |
| Q2 FY2023 | Jun 30, 2023 | $21.98M | +32.6% |
| Q1 FY2023 | Mar 31, 2023 | $26.51M | +43.9% |
| Q4 FY2022 | Dec 31, 2022 | $24.67M | +10.7% |
| Q3 FY2022 | Sep 30, 2022 | $22.20M | +69.7% |
| Q2 FY2022 | Jun 30, 2022 | $16.58M | -8.6% |
| Q1 FY2022 | Mar 31, 2022 | $18.42M | +20.2% |
| Q4 FY2021 | Dec 31, 2021 | $22.30M | +84.3% |
| Q3 FY2021 | Sep 30, 2021 | $13.08M | +48.4% |
| Q2 FY2021 | Jun 30, 2021 | $18.13M | +71.5% |
| Q1 FY2021 | Mar 31, 2021 | $15.33M | +227.8% |
| Q4 FY2020 | Dec 31, 2020 | $12.10M | +112.6% |
| Q3 FY2020 | Sep 30, 2020 | $8.81M | +74.4% |
| Q2 FY2020 | Jun 30, 2020 | $10.57M | +197.4% |
| Q1 FY2020 | Mar 31, 2020 | $4.68M | +20.0% |
| Q4 FY2019 | Dec 31, 2019 | $5.69M | +12.5% |
| Q3 FY2019 | Sep 30, 2019 | $5.05M | +54.8% |
| Q2 FY2019 | Jun 30, 2019 | $3.55M | -12.6% |
| Q1 FY2019 | Mar 31, 2019 | $3.90M | -24.6% |
| Q4 FY2018 | Dec 31, 2018 | $5.06M | +39.2% |
| Q3 FY2018 | Sep 30, 2018 | $3.26M | -16.5% |
| Q2 FY2018 | Jun 30, 2018 | $4.07M | +44.9% |
| Q1 FY2018 | Mar 31, 2018 | $5.17M | +72.7% |
| Q4 FY2017 | Dec 31, 2017 | $3.63M | -25.5% |
| Q3 FY2017 | Sep 30, 2017 | $3.91M | -28.5% |
| Q2 FY2017 | Jun 30, 2017 | $2.81M | – |
| Q1 FY2017 | Mar 31, 2017 | $2.99M | – |
| Q4 FY2016 | Dec 31, 2016 | $4.88M | – |
| Q3 FY2016 | Sep 30, 2016 | $5.47M | – |
See a number that looks wrong?